Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J McPate

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Future Cardiology|October 7, 2009
Short QT syndromeMark J McPate, Harry J Witchel, Jules C Hancox
Journal of Molecular and Cellular Cardiology|July 18, 2006
Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndromeMark J McPate, Rona S Duncan, Harry J Witchel, et al.
Pharmacology & Therapeutics|July 12, 2008
The hERG potassium channel and hERG screening for drug-induced torsades de pointesJules C Hancox, Mark J McPate, Aziza El Harchi, et al.
Plos Computational Biology|December 24, 2011
Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndromeIsmail Adeniran, Mark J McPate, Harry J Witchel, et al.
Journal of Molecular and Cellular Cardiology|March 17, 2009
Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndromeAziza El Harchi, Mark J McPate, Yi hong Zhang, et al.
Biochemical and Biophysical Research Communications|July 14, 2005
The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees CMark J McPate, Rona S Duncan, James T Milnes, et al.
FEBS Letters|March 18, 2006
Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656John M Ridley, James T Milnes, Rona S Duncan, et al.
Journal of Cardiovascular Electrophysiology|May 12, 2010
Acidosis impairs the protective role of hERG K(+) channels against premature stimulationChun Yun Du, Ismail Adeniran, Hongwei Cheng, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Future Cardiology|October 7, 2009
Short QT syndromeMark J McPate, Harry J Witchel, Jules C Hancox
Journal of Molecular and Cellular Cardiology|July 18, 2006
Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndromeMark J McPate, Rona S Duncan, Harry J Witchel, et al.
Pharmacology & Therapeutics|July 12, 2008
The hERG potassium channel and hERG screening for drug-induced torsades de pointesJules C Hancox, Mark J McPate, Aziza El Harchi, et al.
Plos Computational Biology|December 24, 2011
Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndromeIsmail Adeniran, Mark J McPate, Harry J Witchel, et al.
Journal of Molecular and Cellular Cardiology|March 17, 2009
Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndromeAziza El Harchi, Mark J McPate, Yi hong Zhang, et al.
Biochemical and Biophysical Research Communications|July 14, 2005
The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees CMark J McPate, Rona S Duncan, James T Milnes, et al.
FEBS Letters|March 18, 2006
Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656John M Ridley, James T Milnes, Rona S Duncan, et al.
Journal of Cardiovascular Electrophysiology|May 12, 2010
Acidosis impairs the protective role of hERG K(+) channels against premature stimulationChun Yun Du, Ismail Adeniran, Hongwei Cheng, et al.
Pageof 1